Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × canakinumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Lung Neoplasms 4 Triple Negative Breast Neoplasms 1 Rheumatoid Arthritis, Systemic Juvenile 1 Rectal Neoplasms 1 Primary Myelofibrosis 1 Periodic Fevers Syndrome 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Mevalonate Kinase Deficiency 1 Metastatic Pancreatic Ductal Adenocarcinoma 1 Melanoma 1 Leukemia, Myelomonocytic, Chronic 1 Intestinal Neoplasms 1 Gastrointestinal Neoplasms 1 Cryopyrin-Associated Periodic Syndromes 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Clonal Cytopenia of Undetermined Significance 1 Carcinoma, Renal Cell 1 Carcinoma, Ductal 1 Carcinoma 1 Bronchiolitis Obliterans Syndrome 1 Breast Neoplasms 1 Arthritis, Juvenile 1 Arthralgia 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

pembrolizumab 256 Nivolumab 228 Ipilimumab 208 Cyclophosphamide 125 aldesleukin 123 Interleukin-2 92 Dacarbazine 68 trametinib 66 Temozolomide 66 fludarabine 64 Vemurafenib 63 dabrafenib 59 fludarabine phosphate 56 Radiosurgery 43 sargramostim 40 Biopsy 40 Bevacizumab 39 binimetinib 38 incomplete Freund's adjuvant 37 Paclitaxel 35 Cisplatin 34 Radiotherapy 33 encorafenib 31 atezolizumab 31 cobimetinib 30 Magnetic Resonance Spectroscopy 30 Carboplatin 29 Introns 28 Specimen Handling 27 CTLA-4 Antigen 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03484923 2024-06-18

PLATforM

Novartis

Phase 2 Completed

196 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡